ArticleFrontiers in cardiovascular medicine2025
Transcatheter aortic valve replacement via femoral artery for aortic regurgitation post-LVAD: a case report.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 25%-30% of patients experience aortic regurgitation (AR) within the first year after left ventricular assist device (LVAD) implantation. However, there is currently no consensus in clinical guidelines regarding the optimal treatment approach for LVAD-associated AR. Case summary: We report a case of a female patient who developed AR following LVAD implantation. This patient exhibited an open-like configuration of left ventricular outflow tract (LVOT), with no calcified stenosis in the supravalvular region and a lack of anchoring anatomical structures at the junction of the LVOT and sinus-tubular junction. This anatomical configuration posed a high risk of prosthetic valve displacement during conventional transcatheter aortic valve replacement (TAVR). Therefore, we employed a novel TAVR system (Taurus Trio) equipped with a locator, which effectively prevented downward migration of the prosthetic valve after implantation. Discussion: This case indicates the potential advantages and efficacy of the Taurus Trio valve in TAVR for AR Post-LVAD. We plan to conduct long-term follow-up to further explore and optimize the treatment protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.